Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]

Prior treatment

• Previous treatment with triple fixed-dose combination therapy in 12 months prior to screening visit
• Hospitalisation due to COPD exacerbation within the last 30 days prior to enrolment
• Participation in an ongoing clinical interventional or observational trial for another COPD medication (or completed another trial within last 30 days of initiating BGF)
• Previous enrolment in this study

Other illness

• Dementia or other health issues related to memory
• Patient self-reporting or a physician record with an active COVID-19 infection at time of enrolment or hospitalized due to COVID-19 infection in the last 60 days

Other

• Diagnosis of asthma
• Inability to use inhalers
• COPD due to documented α-1 antitrypsin deficiency
• Pregnancy or lactation period

• Physician diagnosis of COPD
• COPD patients in the Best Care Network who have a CAT score \>=10
• Age \>=35 at time of enrolment
• Minimum 12-month recorded prior medical history for patients
• Physician decision and patient agreement to initiate treatment with Breztri based on routine care (and in accordance with label and reimbursement criteria)
• Ability to read English and to provide consent to inclusion in the study